Advertisement

Hormonal therapy for endometriosis: from molecular research to bedside

      Abstract

      Endometriotic lesions are associated with hormonal imbalance, including increased estrogen synthesis, metabolism and progesterone resistance. These hormonal changes cause increased proliferation, inflammation, pain and infertility. Hormonal imbalances are targets for treatment. Therapeutic strategies and innovations of hormonal drugs for endometriosis are increasing.
      Acting on estrogen receptors are hormonal drugs decreasing systemic and local estrogen synthesis (GnRH analogs, GnRH antagonists, Aromatase inhibitors) or estrogen activity (selective estrogen receptor modulators). The progesterone resistance is counteracted by progestins (Medroxyprogesterone acetate, Dienogest, Danazol, Levonorgestrel) or by Selective progesterone receptor modulators, a class of drugs under development.
      The future trend will be to define new drugs to use for prolonged period of time and with poor side effects considering endometriosis a chronic disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      References

        • Tosti C.
        • Pinzauti S.
        • Santulli P.
        • Chapron C.
        • Petraglia F.
        Pathogenetic mechanisms of deep infiltrating endometriosis.
        Reprod Sci. 2015; 22: 1053-1059
        • Burney R.O.
        • Giudice L.C.
        Pathogenesis and pathophysiology of endometriosis.
        Fertil Steril. 2012; 98: 511-519
        • Melis I.
        • Agus M.
        • Pluchino N.
        • et al.
        Alexithymia in women with deep endometriosis? A pilot study.
        J Endometr Pelvic Pain Dis. 2014; 6: 26-33
        • Melis I.
        • Litta P.
        • Nappi L.
        • Agus M.
        • Melis G.B.
        • Angioni S.
        Sexual function in women with deep endometriosis: correlation with quality of life, intensity of pain, depression, anxiety, and body image.
        Int J Sex Health. 2015; 27: 175-185
        • Reis F.M.
        • Petraglia F.
        • Taylor R.N.
        • Endometriosis:
        hormone regulation and clinical consequences of chemotaxis and apoptosis.
        Hum Reprod Update. 2013; 19: 406-418
        • Bulun S.E.
        Endometriosis.
        N Engl J Med. 2009; 360: 268-279
        • Xue Q.
        • Lin Z.
        • Cheng Y.H.
        • et al.
        Promoter methylation regulates estrogen receptor 2 in human endometrium and endometriosis.
        Biol Reprod. 2007; 77: 681-687
        • Han S.J.
        • O’Malley B.W.
        The dynamics of nuclear receptors and nuclear receptor coregulators in the pathogenesis of endometriosis.
        Hum Reprod Update. 2014; 20: 467-484
        • Surrey E.S.
        Gonadotropin-releasing hormone agonist and add-back therapy: what do the data show?.
        Curr Opin Obstet Gynecol. 2010; 22: 283-288
        • Somigliana E.
        • Vigano P.
        • Barbara G.
        • Vercellini P.
        Treatment of endometriosis-related pain: options and outcomes.
        Front Biosci. 2009; 1: 455-465
        • Ferrero S.
        • Alessandri F.
        • Racca A.
        • Leone Roberti Maggiore U.
        Treatment of pain associated with deep endometriosis: alternatives and evidence.
        Fertil Steril. 2015; 104: 771-792
        • Angioni S.
        • Pontis A.
        • Dessole M.
        • Surico D.
        • De Cicco Nardone C.
        • Melis I.
        Pain control and quality of life after laparoscopic en-block resection of deep infiltrating endometriosis (DIE) vs. incomplete surgical treatment with or without GnRHa administration after surgery.
        Arch Gynecol Obstet. 2015; 291: 363-370
        • Streuli I.
        • de Ziegler D.
        • Santulli P.
        • et al.
        An update on the pharmacological management of endometriosis.
        Expert Opin Pharmacother. 2013; 14: 291-305
        • DiVasta A.D.
        • Feldman H.A.
        • Sadler Gallagher J.
        • et al.
        Hormonal add-back therapy for females treated with gonadotropin-releasing hormone agonist for endometriosis: a randomized controlled trial.
        Obstet Gynecol. 2015; 126: 617-627
        • Magon N.
        Gonadotropin releasing hormone agonists: expanding vistas.
        Indian J Endocrinol Metab. 2011; 15: 261-267
        • Kupker W.
        • Felberbaum R.E.
        • Krapp M.
        • Schill T.
        • Malik E.
        • Diedrich K.
        Use of GnRH antagonists in the treatment of endometriosis.
        Reprod Biomed Online. 2002; 5: 12-16
        • Struthers R.S.
        • Nicholls A.J.
        • Grundy J.
        • et al.
        Suppression of gonadotropins and estradiol in premenopausal women by oral administration of the nonpeptide gonadotropin-releasing hormone antagonist elagolix.
        J Clin Endocrinol Metab. 2009; 94: 545-551
        • Diamond M.P.
        • Carr B.
        • Dmowski W.P.
        • et al.
        Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.
        Reprod Sci. 2014; 21: 363-371
        • Quaas A.M.
        • Weedin E.A.
        • Hansen K.R.
        On-label and off-label drug use in the treatment of endometriosis.
        Fertil Steril. 2015; 103: 612-625
        • Abushahin F.
        • Goldman K.N.
        • Barbieri E.
        • Milad M.
        • Rademaker A.
        • Bulun S.E.
        Aromatase inhibition for refractory endometriosis-related chronic pelvic pain.
        Fertil Steril. 2011; 96: 939-942
        • Rocha A.L.
        • Reis F.
        • Petraglia F.
        New trends for the medical treatment of endometriosis.
        Expert Opin Investig Drugs. 2012; 21: 905-919
        • Meresman G.F.
        • Bilotas M.
        • Abello V.
        • Buquet R.
        • Tesone M.
        • Sueldo C.
        Effects of aromatase inhibitors on proliferation and apoptosis in eutopic endometrial cell cultures from patients with endometriosis.
        Fertil Steril. 2005; 84: 459-463
        • Ngo C.
        • Nicco C.
        • Leconte M.
        • et al.
        Antiproliferative effects of anastrozole, methotrexate, and 5-fluorouracil on endometriosis in vitro and in vivo.
        Fertil Steril. 2010; 94: 1632-1680
        • Oner G.
        • Ozcelik B.
        • Ozgun M.T.
        • Serin I.S.
        • Ozturk F.
        • Basbug M.
        The effects of metformin and letrozole on endometriosis and comparison of the two treatment agents in a rat model.
        Hum Reprod. 2010; 25: 932-937
        • Ceyhan S.T.
        • Onguru O.
        • Fidan U.
        • et al.
        Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model.
        Eur J Obstet Gynecol Reprod Biol. 2011; 154: 100-104
        • Razzi S.
        • Fava A.
        • Sartini A.
        • De Simone S.
        • Cobellis L.
        • Petraglia F.
        Treatment of severe recurrent endometriosis with an aromatase inhibitor in a young ovariectomised woman.
        BJOG. 2004; 111: 182-184
        • Bilotas M.
        • Meresman G.
        • Stella I.
        • Sueldo C.
        • Baranao R.I.
        Effect of aromatase inhibitors on ectopic endometrial growth and peritoneal environment in a mouse model of endometriosis.
        Fertil Steril. 2010; 93: 2513-2518
        • Hefler L.A.
        • Grimm C.
        • van Trotsenburg M.
        • Nagele F.
        Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study.
        Fertil Steril. 2005; 84: 1033-1036
        • Verma A.
        • Konje J.C.
        Successful treatment of refractory endometriosis-related chronic pelvic pain with aromatase inhibitors in premenopausal patients.
        Eur J Obstet Gynecol Reprod Biol. 2009; 143: 112-115
        • Ferrero S.
        • Camerini G.
        • Seracchioli R.
        • Ragni N.
        • Venturini P.L.
        • Remorgida V.
        Letrozole combined with norethisterone acetate compared with norethisterone acetate alone in the treatment of pain symptoms caused by endometriosis.
        Hum Reprod. 2009; 24: 3033-3041
        • Soysal S.
        • Soysal M.E.
        • Ozer S.
        • Gul N.
        • Gezgin T.
        The effects of post-surgical administration of goserelin plus anastrozole compared to goserelin alone in patients with severe endometriosis: a prospective randomized trial.
        Hum Reprod. 2004; 19: 160-167
        • Ferrero S.
        • Venturini P.L.
        • Gillott D.J.
        • Remorgida V.
        Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial.
        Reprod Biol Endocrinol. 2011; 9: 88
        • Kulak Jr., J.
        • Fischer C.
        • Komm B.
        • Taylor H.S.
        Treatment with bazedoxifene, a selective estrogen receptor modulator, causes regression of endometriosis in a mouse model.
        Endocrinology. 2011; 152: 3226-3232
        • Yao Z.
        • Shen X.
        • Capodanno I.
        • et al.
        Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds.
        J Invest Surg. 2005; 18: 177-183
        • Stratton P.
        • Sinaii N.
        • Segars J.
        • et al.
        Return of chronic pelvic pain from endometriosis after raloxifene treatment: a randomized controlled trial.
        Obstet Gynecol. 2008; 111: 88-96
        • Zhao Y.
        • Gong P.
        • Chen Y.
        • et al.
        Dual suppression of estrogenic and inflammatory activities for targeting of endometriosis.
        Sci Transl Med. 2015; 7: 271ra9
        • Zhao Y.
        • Chen Y.
        • Kuang Y.
        • et al.
        Multiple beneficial roles of repressor of estrogen receptor activity (REA) in suppressing the progression of endometriosis.
        Endocrinology. 2016; 157: 900-912
        • Attia G.R.
        • Zeitoun K.
        • Edwards D.
        • Johns A.
        • Carr B.R.
        • Bulun S.E.
        Progesterone receptor isoform A but not B is expressed in endometriosis.
        J Clin Endocrinol Metab. 2000; 85: 2897-2902
        • Angioni S.
        • Cofelice V.
        • Pontis A.
        • Tinelli R.
        • Socolov R.
        New trends of progestins treatment of endometriosis.
        Gynecol Endocrinol. 2014; 30: 769-773
        • Bergqvist A.
        • Theorell T.
        Changes in quality of life after hormonal treatment of endometriosis.
        Acta Obstet Gynecol Scand. 2001; 80: 628-637
        • Vercellini P.
        • De Giorgi O.
        • Oldani S.
        • Cortesi I.
        • Panazza S.
        • Crosignani P.G.
        Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
        Am J Obstet Gynecol. 1996; 175: 396-401
        • Crosignani P.G.
        • Luciano A.
        • Ray A.
        • Bergqvist A.
        Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain.
        Hum Reprod. 2006; 21: 248-256
        • Schlaff W.D.
        • Carson S.A.
        • Luciano A.
        • Ross D.
        • Bergqvist A.
        Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain.
        Fertil Steril. 2006; 85: 314-325
        • Lockhat F.B.
        • Emembolu J.E.
        • Konje J.C.
        Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel.
        Fertil Steril. 2005; 83: 398-404
        • Klipping C.
        • Duijkers I.
        • Faustmann T.A.
        • et al.
        Pharmacodynamic study of four oral dosages of dienogest.
        Fertil Steril. 2010; 94: S181
        • Ferrero S.
        • Remorgida V.
        • Venturini P.L.
        • Bizzarri N.
        Endometriosis: the effects of dienogest.
        BMJ Clin Evid. 2015; 2015 (pii:0802)
        • Lazzeri L.
        • Luisi S.
        • Petraglia F.
        Progestins for the treatment of endometriosis: an update.
        J Endometr. 2010; 2: 169-181
        • Andres Mde P.
        • Lopes L.A.
        • Baracat E.C.
        • Podgaec S.
        Dienogest in the treatment of endometriosis: systematic review.
        Arch Gynecol Obstet. 2015; 292: 523-529
        • Hayashi A.
        • Tanabe A.
        • Kawabe S.
        • et al.
        Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosis.
        J Ovarian Res. 2012; 5: 31
        • Köhler G.
        • Faustmann T.A.
        • Gerlinger C.
        • Seitz C.
        • Mueck A.O.
        A dose-ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosis.
        Int J Gynaecol Obstet. 2010; 108: 21-25
        • Momoeda M.
        • Taketani Y.
        • Terakawa N.
        A randomized double-blind, multicenter, parallel, dose-response study of dienogest in patients with endometriosis.
        Jpn Pharmacol Ther. 2007; 35: 796-883
        • Harada T.
        • Taniguchi F.
        Dienogest: a new therapeutic agent for the treatment of endometriosis.
        Womens Health (Lond Engl). 2010; 6: 27-35
        • Strowitzki T.
        • Faustmann T.
        • Gerlinger C.
        • Seitz C.
        Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study.
        Eur J Obstet Gynecol Reprod Biol. 2010; 151: 193-198
        • Harada T.
        • Momoeda M.
        • Taketani Y.
        • et al.
        Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis-a randomized, double-blind, multicenter, controlled trial.
        Fertil Steril. 2009; 91: 675-681
        • Strowitzki T.
        • Marr J.
        • Gerlinger C.
        • Faustmann T.
        • Seitz C.
        Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial.
        Hum Reprod. 2010; 25: 633-641
        • Luisi S.
        • Parazzini F.
        • Angioni S.
        • et al.
        Dienogest treatment improves quality of life in women with endometriosis.
        J Endometr Pelvic Pain Dis. 2015;
        • Momoeda M.
        • Harada T.
        • Terakawa N.
        • et al.
        Long-term use of dienogest for the treatment of endometriosis.
        J Obstet Gynaecol Res. 2009; 35: 1069-1076
        • Petraglia F.
        • Hornung D.
        • Seitz C.
        • et al.
        Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatment.
        Arch Gynecol Obstet. 2012; 285: 167-173
        • Harada M.
        • Osuga Y.
        • Izumi G.
        • et al.
        Dienogest, a new conservative strategy for extragenital endometriosis: a pilot study.
        Gynecol Endocrinol. 2011; 27: 717-720
        • Angioni S.
        • Nappi L.
        • Pontis A.
        • et al.
        Dienogest. A possible conservative approach in bladder endometriosis. Results of a pilot study.
        Gynecol Endocrinol. 2015; 31: 406-408
        • Cosson M.
        • Querleu D.
        • Donnez J.
        • et al.
        Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study.
        Fertil Steril. 2002; 77: 684-692
        • Stanczyk F.Z.
        • Roy S.
        Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids.
        Contraception. 1990; 42: 67-96
        • Muneyyirci-Delaleand O.
        • Karacan M.
        Effect of norethindrone acetate in the treatment of symptomatic endometriosis.
        Int J Fertil Womens Med. 1998; 43: 24-27
        • Vercellini P.
        • Pietropaolo G.
        • DeGiorgi O.
        • Pasin R.
        • Chiodini A.
        • Crosignani P.G.
        Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate.
        Fertil Steril. 2005; 84: 1375-1387
        • Ferrero S.
        • Camerini G.
        • Ragni N.
        • Venturini P.L.
        • Biscaldi E.
        • Remorgida V.
        Norethisterone acetate in the treatment of colorectal endometriosis: a pilot study.
        Hum Reprod. 2010; 25: 94-100
        • Vercellini P.
        • Fedele L.
        • Pietropaolo G.
        • Frontino G.
        • Somigliana E.
        • Crosignani P.G.
        Progestogens for endometriosis: forward to the past.
        Hum Reprod Update. 2003; 9: 387-396
        • Farquhar C.
        • Prentice A.
        • Singla A.A.
        • Selak V.
        Danazol for pelvic pain associated with endometriosis.
        Cochrane Database Syst Rev. 2007; 4: CD000068
        • Igarashi M.
        • Abe Y.
        • Fukuda M.
        • et al.
        Novel conservative medical therapy for uterine adenomyosis with a danazol-loaded intrauterine device.
        Fertil Steril. 2000; 74: 851
        • Igarashi M.
        • Iizuka M.
        • Abe Y.
        • Ibuki Y.
        Novel vaginal danazol ring therapy for pelvic endometriosis, in particular deeply infiltrating endometriosis.
        Hum Reprod. 1998; 13: 1952-1956
        • Cobellis L.
        • Razzi S.
        • Fava A.
        • Severi F.M.
        • Igarashi M.
        • Petraglia F.
        A danazol-loaded intrauterine device decreases dysmenorrhea, pelvic pain, and dyspareunia associated with endometriosis.
        Fertil Steril. 2004; 82: 239-240
        • Razzi S.
        • Luisi S.
        • Calonaci F.
        • Altomare A.
        • Bocchi C.
        • Petraglia F.
        Efficacy of vaginal danazol treatment in women with recurrent deeply infiltrating endometriosis.
        Fertil Steril. 2007; 88: 789-794
        • Luisi S.
        • Razzi S.
        • Lazzeri L.
        • Bocchi C.
        • Severi F.M.
        • Petraglia F.
        Efficacy of vaginal danazol treatment in women with menorrhagia during fertile age.
        Fertil Steril. 2009; 92: 1351-1354
        • Gomes M.K.
        • Rosa-e-Silva J.C.
        • Garcia S.B.
        • et al.
        Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium.
        Hum Reprod. 2009; 24: 2736-2745
        • Vercellini P.
        • Frontino G.
        • De Giorgi O.
        • Aimi G.
        • Zaina B.
        • Crosignani P.G.
        Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study.
        Fertil Steril. 2003; 80: 305-309
        • Lockhat F.B.
        • Emembolu J.O.
        • Konje J.C.
        The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease.
        Hum Reprod. 2004; 19: 179-184
        • Matorras R.
        • Ballesteros A.
        • Prieto B.
        • et al.
        Efficacy of the levonorgestrel-releasing intrauterine device in the treatment of recurrent pelvic pain in multitreated endometriosis.
        J Reprod Med. 2011; 56: 497-503
        • Lockhat F.B.
        • Emembolu J.O.
        • Konje J.C.
        The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up.
        Hum Reprod. 2005; 20: 789-793
        • Bayoglu Tekin Y.
        • Dilbaz B.
        • Altinbas S.K.
        • Dilbaz S.
        Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue.
        Fertil Steril. 2011; 95: 492-496
        • Petta C.A.
        • Ferriani R.A.
        • Abrao M.S.
        • et al.
        Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis.
        Hum Reprod. 2005; 20: 1993-1998
        • Petta C.A.
        • Ferriani R.A.
        • Abrao M.S.
        • et al.
        A 3-year follow-up of women with endometriosis and pelvic pain users of the levonorgestrel-releasing intrauterine system.
        Eur J Obstet Gynecol Reprod Biol. 2009; 143: 128-129
        • de Sa Rosa e Silva A.C.
        • Rosa e Silva J.C.
        • Nogueira A.A.
        • Petta C.A.
        • Abrao M.S.
        • Ferriani R.A.
        The levonorgestrel-releasing intrauterine device reduces CA-125 serum levels in patients with endometriosis.
        Fertil Steril. 2006; 86: 742-744
        • Bouchard P.
        • Chabbert-Buffet N.
        • Fauser B.C.
        Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety.
        Fertil Steril. 2011; 96: 1175-1189
        • Madauss K.P.
        • Grygielko E.T.
        • Deng S.J.
        • et al.
        A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.
        Mol Endocrinol. 2007; 21: 1066-1081
        • Kettel L.M.
        • Murphy A.A.
        • Morales A.J.
        • Ulmann A.
        • Baulieu E.E.
        • Yen S.S.
        Treatment of endometriosis with the antiprogesterone mifepristone (RU486).
        Fertil Steril. 1996; 65: 23-28
        • Kettel L.M.
        • Murphy A.A.
        • Morales A.J.
        • Yen S.S.
        Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486).
        Am J Obstet Gynecol. 1998; 178: 1151-1156
        • Mei L.
        • Bao J.
        • Tang L.
        • et al.
        A novel mifepristone-loaded implant for long-term treatment of endometriosis: in vitro and in vivo studies.
        Eur J Pharm Sci. 2010; 39: 421-427
        • Chwalisz K.
        • Mattia-Goldberg C.
        • Elger W.
        • Edmonds A.
        Treatment of endometriosis with the novel selective progesterone receptor modulator (SPRM) asoprisnil.
        Fertil Steril. 2004; 82: S83-S84
        • Wilkens J1
        • Critchley H.
        Progesterone receptor modulators in gynaecological practice.
        J Fam Plann Reprod Health Care. 2010; 36: 87-92
        • Seracchioli R.
        • Mabrouk M.
        • Manuzzi L.
        • et al.
        Post-operative use of oral contraceptive pills for prevention of anatomical relapse or symptom-recurrence after conservative surgery for endometriosis.
        Hum Reprod. 2009; 24: 2729-2735